Skip to main content
Fig. 4 | BMC Pediatrics

Fig. 4

From: Evaluating the effect of recombinant human growth hormone treatment on sleep-related breathing disorders in toddlers with Prader–Willi syndrome: a one-year retrospective cohort study

Fig. 4

Comparsion of rhGH treatment on PSG results at the baseline, 26 weeks and 52 weeks after the treatment. No significant difference of the OAHI (a), OAI (b), ODI (c) and time of spO2 less than 90% (d) was found among the pre-treatment, 26-week and 52-week after the treatment. ns: no significance

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us